CCXI Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 8.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

ChemoCentryx Insider Trading History Chart

This chart shows the insider buying and selling history at ChemoCentryx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

ChemoCentryx Share Price & Price History

Current Price: $51.99
Price Change: +0.30 (1.20%)
As of 11/2/2022 01:00 AM ET

This chart shows the closing price history over time for CCXI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

ChemoCentryx Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for ChemoCentryx (NASDAQ:CCXI)

81.09% of ChemoCentryx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CCXI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500M$0$500MTotal InflowsTotal Outflows
ChemoCentryx logo
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Read More on ChemoCentryx

Today's Range

Now: $51.99
Low: $51.99
High: $51.99

50 Day Range

MA: $51.95
Low: $51.66
High: $51.99

52 Week Range

Now: $51.99
Low: $14.95
High: $52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22